QIAGEN Adds Novel Technology for Haplotype Specific Extraction (HSE)
QIAGEN N.V. announced that its wholly owned subsidiary GenoVision Inc. has licensed a novel technology for haplotype specific extraction of DNA (HSE) from Generation Biotech, LLC. Under the terms of the license agreement QIAGEN's wholly owned subsidiary received exclusive rights for the worldwide commercialization of HSE in all applications.
QIAGEN believes that this technology provides a significant new dimension in increased resolution and quality of genetic analysis in diagnostics. It addresses an increasingly important, previously unmet need. This novel preanalytical technology has been validated for use in concert with a suite of QIAGEN's leading magnetic bead-based and automated DNA purification solutions.
Many diseases and differences in patients' drug respond rates are related to mutations on several genes of the genome. The exact determination of mutations located either on the same chromosome or on different chromosomes is of highest importance in areas such as clinical prognosis of diseases, HLA typing prior to transplantations, pharmacogenomics and oncology testing. Using a proprietary and validated approach developed at Princeton University and Generation Biotech, the licensed Haplotype Specific Extraction (HSE) method physically separates DNA into its maternal and paternal alleles and enables clinicians and researchers in academic and clinical research and molecular diagnostics to determine the exact location of a mutation on both copies of the genome. This allows a significant new dimension of quality in terms of the information generated in the analysis.
Other news from the department research and development
